BR0010391A - Composto, composição farmacêutica, método de preparação de um composto, e, uso de um composto - Google Patents

Composto, composição farmacêutica, método de preparação de um composto, e, uso de um composto

Info

Publication number
BR0010391A
BR0010391A BR0010391-8A BR0010391A BR0010391A BR 0010391 A BR0010391 A BR 0010391A BR 0010391 A BR0010391 A BR 0010391A BR 0010391 A BR0010391 A BR 0010391A
Authority
BR
Brazil
Prior art keywords
compound
carbon atoms
ring
optionally
preparing
Prior art date
Application number
BR0010391-8A
Other languages
English (en)
Inventor
Francis Thomas Boyle
Keith Hopkinson Gibson
Jeffrey Philip Poyser
Paul Turner
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of BR0010391A publication Critical patent/BR0010391A/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/48—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • C07D215/54—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen attached in position 3
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Quinoline Compounds (AREA)
  • Luminescent Compositions (AREA)
  • Saccharide Compounds (AREA)

Abstract

"COMPOSTO, COMPOSIçãO FARMACêUTICA, MéTODO DE PREPARAçãO DE UM COMPOSTO, E, USO DE UM COMPOSTO". Um composto de fórmula (I): ou um sal farmaceuticamente aceitável deste em que: n é de 0 a 1. X e Y são independentemente selecionados de NH-, -O-, -S-, ou NR^ 8^ - onde R^ 8^ é alquila de 1 a 6 átomos de carbono e X pode opcionalmente compreender um grupo CH~ 2~; R^ 7^ é um grupo ( CH~ 2~ )~ m~R^ 9^ onde m é 0, ou um número inteiro de 1 a 3 e R^ 9^ é um grupo arila substituída, um anel de cicloalquila opcionalmente substituído de até 10 átomos de carbono, ou um anel heterocíclico opcionalmente substituído ou um N-óxido de qualquer anel contendo nitrogênio; R^ 6^ é uma cicloalquila divalente de 3 a 7 átomos de carbono, que pode ser opcionalmente ainda substituído por um ou mais grupos de alquila de 1 a 6 átomos de carbono; ou é um anel divalente de piridinila, pirimidinila ou fenila; em que o anel de piridinila, pirimidinila ou fenila pode ser opcionalmente ainda substituído por um ou mais grupos específicos; R~ 1~, R~ 2~, R~ 3~ e R~ 4~ são, cada um, independentemente selecionados de hidrogênio ou vários grupos orgânicos específicos. Os compostos são úteis como produtos farmacêuticos para a inibição da atividade MEK.
BR0010391-8A 1999-05-08 2000-05-03 Composto, composição farmacêutica, método de preparação de um composto, e, uso de um composto BR0010391A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB9910577.7A GB9910577D0 (en) 1999-05-08 1999-05-08 Chemical compounds
PCT/GB2000/001697 WO2000068201A1 (en) 1999-05-08 2000-05-03 Quinoline derivatives as inhibitors of mek enzymes

Publications (1)

Publication Number Publication Date
BR0010391A true BR0010391A (pt) 2002-07-02

Family

ID=10852987

Family Applications (1)

Application Number Title Priority Date Filing Date
BR0010391-8A BR0010391A (pt) 1999-05-08 2000-05-03 Composto, composição farmacêutica, método de preparação de um composto, e, uso de um composto

Country Status (26)

Country Link
EP (2) EP1584619A1 (pt)
JP (1) JP2002544196A (pt)
KR (1) KR100667719B1 (pt)
CN (1) CN1219768C (pt)
AT (1) ATE319688T1 (pt)
AU (1) AU772846B2 (pt)
BG (1) BG106073A (pt)
BR (1) BR0010391A (pt)
CA (1) CA2372663A1 (pt)
CZ (1) CZ20013997A3 (pt)
DE (1) DE60026509T2 (pt)
DK (1) DK1178967T3 (pt)
EE (1) EE200100589A (pt)
ES (1) ES2258455T3 (pt)
GB (2) GB9910577D0 (pt)
HU (1) HUP0201219A3 (pt)
IL (1) IL146317A0 (pt)
IS (1) IS6138A (pt)
NO (1) NO321696B1 (pt)
NZ (1) NZ514980A (pt)
PL (1) PL352413A1 (pt)
PT (1) PT1178967E (pt)
SK (1) SK16102001A3 (pt)
TR (1) TR200103186T2 (pt)
WO (1) WO2000068201A1 (pt)
ZA (1) ZA200108971B (pt)

Families Citing this family (83)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1365796A2 (en) 2000-09-01 2003-12-03 Van Andel Institute Inhibition of mitogen-activated protein kinase (mapk) pathway: a selective therapeutic strategy against melanoma
US7067532B2 (en) 2000-11-02 2006-06-27 Astrazeneca Substituted quinolines as antitumor agents
WO2002036570A1 (en) * 2000-11-02 2002-05-10 Astrazeneca Ab 4-substituted quinolines as antitumor agents
WO2002053528A1 (en) 2000-12-29 2002-07-11 Wyeth Method for the regioselective preparation of substituted benzo[g]quinoline-3-carbonitriles and benzo[g]quinazolines
WO2002076496A1 (en) * 2001-03-22 2002-10-03 Van Andel Institute Anthrax lethal factor inhibits tumor growth and angiogenesis
GB0112834D0 (en) 2001-05-25 2001-07-18 Smithkline Beecham Plc Medicaments
WO2003000705A1 (en) 2001-06-21 2003-01-03 Ariad Pharmaceuticals, Inc. Novel quinolines and uses thereof
ES2272737T3 (es) 2001-07-16 2007-05-01 Astrazeneca Ab Derivados de quinolina y su uso como inhibidores de tirosina quinasas.
US6821988B2 (en) * 2001-11-27 2004-11-23 Wyeth Holdings Corporation 3-cyanoquinolines as inhibitors of EGF-R and HER2 kinases
AU2002365664A1 (en) * 2001-12-05 2003-06-17 Astrazeneca Ab Quinoline derivatives as antitumour agents
AU2002347359A1 (en) * 2001-12-05 2003-06-17 Astrazeneca Ab Quinoline derivatives
AU2002347336A1 (en) * 2001-12-05 2003-06-17 Astrazeneca Ab Quinoline derivatives
SG2013013339A (en) 2002-03-13 2014-12-30 Array Biopharma Inc N3 alkylated benzimidazole derivatives as mek inhibitors
US7235537B2 (en) 2002-03-13 2007-06-26 Array Biopharma, Inc. N3 alkylated benzimidazole derivatives as MEK inhibitors
NZ536114A (en) * 2002-03-30 2007-11-30 Boehringer Ingelheim Pharma 4-(N-phenylamino)-quinazolines / quinolines as tyrosine kinase inhibitors
US6924285B2 (en) 2002-03-30 2005-08-02 Boehringer Ingelheim Pharma Gmbh & Co. Bicyclic heterocyclic compounds, pharmaceutical compositions containing these compounds, their use and process for preparing them
GB0215823D0 (en) 2002-07-09 2002-08-14 Astrazeneca Ab Quinazoline derivatives
EP1521747B1 (en) 2002-07-15 2018-09-05 Symphony Evolution, Inc. Receptor-type kinase modulators and methods of use
GB0225579D0 (en) 2002-11-02 2002-12-11 Astrazeneca Ab Chemical compounds
WO2004069249A1 (en) * 2003-02-03 2004-08-19 Astrazeneca Ab 3-cyano-quinoline derivatives as non-receptor tyrosine kinase inhibitors
WO2004069250A1 (en) * 2003-02-03 2004-08-19 Astrazeneca Ab 3-cyano-quinoline derivatives as non-receptor tyrosine kinase inhibitors
EP1636195A1 (en) * 2003-05-27 2006-03-22 Pfizer Products Inc. Quinazolines and pyrido[3,4-d]pyrimidines as receptor tyrosine kinase inhibitors
US7538120B2 (en) 2003-09-03 2009-05-26 Array Biopharma Inc. Method of treating inflammatory diseases
US7144907B2 (en) 2003-09-03 2006-12-05 Array Biopharma Inc. Heterocyclic inhibitors of MEK and methods of use thereof
EP2210607B1 (en) 2003-09-26 2011-08-17 Exelixis Inc. N-[3-fluoro-4-({6-(methyloxy)-7-[(3-morpholin-4-ylpropyl)oxy]quinolin-4-yl}oxy)phenyl]-N'-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide for the treatment of cancer
US7517994B2 (en) 2003-11-19 2009-04-14 Array Biopharma Inc. Heterocyclic inhibitors of MEK and methods of use thereof
KR101190912B1 (ko) 2003-11-19 2012-10-12 어레이 바이오파마 인크. Ｍｅｋ의 헤테로시클릭 억제제 및 그의 사용 방법
US7732616B2 (en) 2003-11-19 2010-06-08 Array Biopharma Inc. Dihydropyridine and dihydropyridazine derivatives as inhibitors of MEK and methods of use thereof
AU2004293026B2 (en) 2003-11-21 2012-01-19 Array Biopharma Inc. AKT protein kinase inhibitors
CN1930128A (zh) 2004-01-16 2007-03-14 惠氏公司 受体酪氨酸激酶抑制剂的喹啉中间体及其合成
TW200529846A (en) 2004-02-20 2005-09-16 Wyeth Corp 3-quinolinecarbonitrile protein kinase inhibitors
ES2444866T3 (es) 2004-10-20 2014-02-27 Merck Serono Sa Derivados de 3-arilamino piridina
FR2884516B1 (fr) * 2005-04-15 2007-06-22 Cerep Sa Antagonistes npy, preparation et utilisations
TWI441637B (zh) 2005-05-18 2014-06-21 Array Biopharma Inc Ｍｅｋ雜環抑制劑及其使用方法
AR057455A1 (es) * 2005-07-22 2007-12-05 Merck & Co Inc Inhibidores de la transcriptasa reversa de vih y composicion farmaceutica
DE602006021645D1 (de) 2005-11-15 2011-06-09 Array Biopharma Inc Verfahren und Zwischenverbindungen zur Herstellung von N4-Phenyl-Quinazolin-4-Amin Derivaten
US20090239936A1 (en) 2006-05-15 2009-09-24 Yoshikazu Sugimoto Prophylactic and Therapeutic Agent for Cancer
WO2008006039A1 (en) 2006-07-06 2008-01-10 Array Biopharma Inc. Dihydrothieno pyrimidines as akt protein kinase inhibitors
US8063050B2 (en) 2006-07-06 2011-11-22 Array Biopharma Inc. Hydroxylated and methoxylated pyrimidyl cyclopentanes as AKT protein kinase inhibitors
RU2481336C2 (ru) 2006-07-06 2013-05-10 Эррэй Биофарма Инк. Циклопента(d)пиримидины в качестве ингибиторов протеинкиназ акт
DE602007011628D1 (de) 2006-07-06 2011-02-10 Array Biopharma Inc Dihydrofuropyrimidine als akt-proteinkinaseinhibitoren
EP1921070A1 (de) 2006-11-10 2008-05-14 Boehringer Ingelheim Pharma GmbH & Co. KG Bicyclische Heterocyclen, diese Verbindungen enthaltende Arzneimittel, deren Verwendung und Verfahren zu ihrer Herstelllung
JP5377332B2 (ja) 2007-02-06 2013-12-25 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 二環式へテロ環、それらの化合物を含む薬剤、その使用及びその製法
EP1969932A1 (de) * 2007-03-12 2008-09-17 Bayer CropScience AG Phenoxyphenylamidine und deren Verwendung als Fungizide
WO2008110280A2 (de) * 2007-03-12 2008-09-18 Bayer Cropscience Ag Phenoxy-substitutierte phenylamidin-derivativen und deren verwendung als fungiziden
US8846683B2 (en) 2007-07-05 2014-09-30 Array Biopharma, Inc. Pyrimidyl cyclopentanes as Akt protein kinase inhibitors
MX2009014013A (es) 2007-07-05 2010-01-28 Array Biopharma Inc Pirimidil ciclopentanos como inhibidores de la proteina cinasa akt.
CA2692502C (en) 2007-07-05 2016-03-01 Array Biopharma Inc. Pyrimidyl cyclopentanes as akt protein kinase inhibitors
US9409886B2 (en) 2007-07-05 2016-08-09 Array Biopharma Inc. Pyrimidyl cyclopentanes as AKT protein kinase inhibitors
EP2220047B1 (en) 2007-11-15 2015-05-06 ClanoTech AB Quinoline derivatives, pharmaceutical compositions comprising them, and use thereof
CN101952274A (zh) 2007-11-20 2011-01-19 默沙东公司 非核苷逆转录酶抑制剂
US8853216B2 (en) 2008-01-09 2014-10-07 Array Biopharma, Inc. Hydroxylated pyrimidyl cyclopentane as AKT protein kinase inhibitor
US8835434B2 (en) 2008-01-09 2014-09-16 Array Biopharma, Inc. Hydroxylated pyrimidyl cyclopentanes as akt protein kinase inhibitors
WO2009098061A1 (de) 2008-02-07 2009-08-13 Boehringer Ingelheim International Gmbh Spirocyclische heterocyclen, diese verbindungen enthaltende arzneimittel, deren verwendung und verfahren zu ihrer herstellung
AU2009279940B2 (en) 2008-08-04 2014-01-16 Merck Patent Gmbh Novel phenylamino isonicotinamide compounds
EP2313397B1 (de) 2008-08-08 2016-04-20 Boehringer Ingelheim International GmbH Cyclohexyloxy-substituierte heterocyclen, diese verbindungen enthaltende arzneimittel, deren verwendung und verfahren zu ihrer herstellung
EP2346818B1 (en) 2008-11-10 2012-12-05 Bayer Intellectual Property GmbH Substituted sulphonamido phenoxybenzamides
TW201920110A (zh) 2009-01-16 2019-06-01 美商艾克塞里克斯公司 包含n-(4-{[6,7-雙(甲氧基)喹啉-4-基]氧基}苯基)-n'-(4-氟苯基)環丙烷-1,1-二甲醯胺之蘋果酸鹽之醫藥組合物及其用途
UA108618C2 (uk) 2009-08-07 2015-05-25 Застосування c-met-модуляторів в комбінації з темозоломідом та/або променевою терапією для лікування раку
US8962606B2 (en) 2009-10-21 2015-02-24 Bayer Intellectual Property Gmbh Substituted benzosulphonamides
CN102574782B (zh) 2009-10-21 2014-10-08 拜耳知识产权有限责任公司 取代的卤代苯氧基苯甲酰胺衍生物
CA2777430A1 (en) 2009-10-21 2011-04-28 Bayer Pharma Aktiengesellschaft Substituted benzosulphonamides
EP2509961B1 (en) * 2009-12-11 2016-03-09 Autifony Therapeutics Limited Imidazolidinedione derivatives
US9187458B2 (en) 2010-06-09 2015-11-17 Tianjin Hemay Bio-Tech Co., Ltd. Cyanoquinoline derivatives
WO2012055953A1 (en) 2010-10-29 2012-05-03 Bayer Pharma Aktiengesellschaft Substituted phenoxypyridines
CN102020651B (zh) 2010-11-02 2012-07-18 北京赛林泰医药技术有限公司 6-芳基氨基吡啶酮甲酰胺mek抑制剂
FI2694072T4 (fi) 2011-04-01 2024-09-30 Genentech Inc Akt-inhibiittoriyhdisteen ja abirateronin yhdistelmä käytettäväksi terapeuttisissa hoidoissa
TR201815685T4 (tr) 2011-04-01 2018-11-21 Genentech Inc Kanser tedavisi için akt ve mek inhibe edici bileşiklerin kombinasyonları.
EP2714037B1 (en) 2011-05-25 2016-07-13 Université Paris Descartes Erk inhibitors for use in treating spinal muscular atrophy
CN103204825B (zh) 2012-01-17 2015-03-04 上海科州药物研发有限公司 作为蛋白激酶抑制剂的苯并噻唑化合物及其制备方法和用途
WO2015038704A1 (en) 2013-09-11 2015-03-19 The J. David Gladstone Institutes, A Testamentary Trust Established Under The Will Of J. David Gladstone Compositions for preparing cardiomyocytes
WO2015108907A2 (en) 2014-01-14 2015-07-23 Dana-Farber Cancer Institute, Inc. Compositions and methods for identification, assessment, prevention, and treatment of melanoma using pd-l1 isoforms
US20170248603A1 (en) 2014-10-06 2017-08-31 Dana-Farber Cancer Institute, Inc. Angiopoiten-2 biomarkers predictive of anti-immune checkpoint response
MA41866A (fr) 2015-03-31 2018-02-06 Massachusetts Gen Hospital Molécules à auto-assemblage pour l'administration ciblée de médicaments
WO2017040982A1 (en) * 2015-09-02 2017-03-09 The Regents Of The University Of California Her3 ligands and uses thereof
US20190112317A1 (en) 2015-10-05 2019-04-18 The Trustees Of Columbia University In The City Of New York Activators of autophagic flux and phospholipase d and clearance of protein aggregates including tau and treatment of proteinopathies
CN109422755B (zh) * 2017-09-01 2023-07-04 上海医药集团股份有限公司 一种含氮杂环化合物、制备方法、中间体、组合物和应用
CA3129665A1 (en) 2019-03-21 2020-09-24 Onxeo A dbait molecule in combination with kinase inhibitor for the treatment of cancer
KR20220098759A (ko) 2019-11-08 2022-07-12 인쎄름 (엥스띠뛰 나씨오날 드 라 쌍떼 에 드 라 흐쉐르슈 메디깔) 키나제 억제제에 대해 내성을 획득한 암의 치료 방법
WO2021148581A1 (en) 2020-01-22 2021-07-29 Onxeo Novel dbait molecule and its use
TW202342018A (zh) 2022-03-04 2023-11-01 美商奇奈特生物製藥公司 Mek激酶抑制劑
EP4788839A1 (en) 2023-10-03 2026-08-12 Institut National de la Santé et de la Recherche Médicale Methods of prognosis and treatment of patients suffering from melanoma
WO2026017799A1 (en) * 2024-07-18 2026-01-22 Centre Hospitalier Universitaire Vaudois Substituted 3-cyanoquinolines for the prevention and treatment of sexually transmitted diseases

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1252054C (zh) * 1996-09-25 2006-04-19 曾尼卡有限公司 抑制生长因子的作用的喹啉衍生物
UA73073C2 (uk) * 1997-04-03 2005-06-15 Уайт Холдінгз Корпорейшн Заміщені 3-ціанохіноліни, спосіб їх одержання та фармацевтична композиція
ES2229515T3 (es) * 1997-07-01 2005-04-16 Warner-Lambert Company Llc Derivados 4-bromo o 4-yodo del acido fenilamino benzhidroxamico y su uso como inhibidores de la mek.
CZ303899B6 (cs) * 1998-09-29 2013-06-19 Wyeth Holdings Corporation Substituovaný 3-kyanochinolin, zpusob jeho prípravy a farmaceutická kompozice s jeho obsahem
HU230728B1 (hu) * 1998-09-29 2017-12-28 Wyeth Holdings Llc Szubsztituált 3-cianokinolinok mint protein tirozin kinázok inhibitorai

Also Published As

Publication number Publication date
TR200103186T2 (tr) 2002-04-22
KR100667719B1 (ko) 2007-02-28
JP2002544196A (ja) 2002-12-24
CA2372663A1 (en) 2000-11-16
SK16102001A3 (sk) 2002-06-04
EE200100589A (et) 2003-02-17
NO20015448L (no) 2002-01-07
NO20015448D0 (no) 2001-11-07
EP1584619A1 (en) 2005-10-12
ZA200108971B (en) 2003-01-30
AU772846B2 (en) 2004-05-06
CZ20013997A3 (cs) 2002-02-13
CN1365355A (zh) 2002-08-21
GB9910577D0 (en) 1999-07-07
IL146317A0 (en) 2002-07-25
CN1219768C (zh) 2005-09-21
AU4589100A (en) 2000-11-21
GB0009532D0 (en) 2000-06-07
PL352413A1 (en) 2003-08-25
EP1178967B1 (en) 2006-03-08
DE60026509D1 (de) 2006-05-04
DK1178967T3 (da) 2006-06-26
WO2000068201A1 (en) 2000-11-16
ES2258455T3 (es) 2006-09-01
KR20010110811A (ko) 2001-12-13
ATE319688T1 (de) 2006-03-15
DE60026509T2 (de) 2006-11-16
NO321696B1 (no) 2006-06-26
PT1178967E (pt) 2006-06-30
BG106073A (en) 2002-05-31
IS6138A (is) 2001-10-30
NZ514980A (en) 2003-10-31
EP1178967A1 (en) 2002-02-13
HUP0201219A2 (en) 2002-09-28
HUP0201219A3 (en) 2003-05-28

Similar Documents

Publication Publication Date Title
PT1178967E (pt) Derivados de quinolina como inibidores de enzimas mek
TW200716528A (en) Cyclopropanecarboxamide derivatives
BR0306208A (pt) Compostos de dibenzilamina e seu uso farmacêutico
BRPI0414450A (pt) derivados de diazabicicloalcano substituìdos como ligandos nos receptores de alfa 7 acetilcolina nicotìnica
BR0213877A (pt) Compostos orgânicos
BR0315405A (pt) Compostos inibidores da integrase tricìclica pré-organizados
BRPI0510598A (pt) compostos de amida de aril ou heteroaril substituìdos
CO5251463A1 (es) Compuestos heterociclicos y composicion farmaceutica que coniene dichos compuestos
MA32249B1 (fr) Dérivés polysubstitues de 2-heteroaryl-6-phenyl-imidazo[1,2- a]pyridines, leur préparation et leur application en thérapeutique
BRPI0509307A (pt) compostos de alfa aril ou heteroaril metil beta piperidino propanamida como antagonistas do receptor orl1
BRPI0517232A (pt) composto ou um sal farmaceuticamente aceitável do mesmo, composição farmacêutica, ativador da glicocinase, e, agentes terapêuticos e/ou profiláticos para diabetes e para obesidade
BRPI0408605A (pt) derivados de 8-perfluoralquil-6,7,8,9-tetrahidropirimido[1,2-a]piri midin-4-ona substituìdos
TW200612920A (en) Novel imidazolidine derivatives
DK1204662T3 (da) Azaindoler med serotoninreceptoraffinitet
AR047531A1 (es) Derivados 1h-tieno(2,3-c)pirazol utiles como inhibidores de quinasa
ATE240949T1 (de) Epoxysuccinamid-derivate oder ihre salze
ATE194982T1 (de) Benzoxazepin-derivate als cholinesterase- inhibitoren
BRPI0415109A (pt) compostos de 1-[2-(4-hidroxifenil)-2-hidroxietil]-piperidin-4-ol como antagonistas de receptor de nmda
CO5080802A1 (es) Nuevos compuestos heterociclicos inhibidores de la fosfodiesteresa iv y su formulacion y uso como productos farmaceuticos
DK601283D0 (da) Pyridinderivater
BR0308935A (pt) Inibidor de fosfodiesterase iv contendo derivado de piridilacrilamida
NO20053302D0 (no) Imidazolderivater med affinitet for alfa 2-reseptoraktivitet.
BR112019006675A2 (pt) derivado heterocíclico nitrogenado bicíclico e composição farmacêutica contendo o mesmo
TH37500A (th) อนุพันธ์ซิส-ซับสทิทิวเทด ซับสทิทิวเทด อะมิโนไซโคลแอลคิล พิร์โรลิอีน
AR020415A1 (es) Compuestos de diarilmetilidenfurano, procesos para su preparacion, las composiciones farmaceuticas que los contienen y los metodos de tratamientoterapeutico que utilizan dichos compuestos.

Legal Events

Date Code Title Description
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]

Free format text: INDEFIRO O PEDIDO DE ACORDO COM O(S) ARTIGO(S) 8O, 13, 24 E 25 DA LPI.

B09B Patent application refused [chapter 9.2 patent gazette]

Free format text: MANTIDO O INDEFERIMENTO UMA VEZ QUE NAO FOI APRESENTADO RECURSO DENTRO DO PRAZO LEGAL.